Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Chuca Marsh who wrote (1250)	6/2/1999 8:33:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

To me it's not inconceivable that Inflazyme could get a buy recommendation from an important analyst, as opposed to Neil Maedel. If and when that happens he'll be forgotten completely. An example of a Maedel Rec: He recommended LMX, a mining company, several years ago, when it was about $2.80. Now it's 15 cents. To his credit he put out a sell, after it lost more than half its value.

To: Chuca Marsh who wrote (1250)	6/3/1999 10:15:00 AM
From: David Graham	Read Replies (1) \| Respond to of 1501

Chuca, tsk, tsk :-). Hinting that I might be an IR guy - yikes. No, I'm a plain old investor who's been posting on this thread almost as long as you - though not quite so frequently as you. The sell was in his May 27 newsletter. Harold - he didn't say the company was a bad bet, the point is that its share price is driven by news, and other than a temporary boost from a TSE listing, the news pipeline is expected to be dry for almost a year. You've held this stock a long time, you know what happens when there's no useful news - down, slowly, inexorably down. If it gets cheaper I'll likely buy back in. David